[Retracted] Correlation Analysis of Acute Coronary Syndrome with Serum IL‐18, MMP‐9, hs‐CRP, and Plasma FIB

Yang, Yuexia; Li, Guoming; Zhang, Ruiqin

doi:10.1155/2022/5984184

Cited by 5 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The broad biological role of the IL-18 cytokine on immune cells have revealed its potential role in inflammatory and autoimmune diseases. IL-18 have been shown to be a diagnostic marker and predictor of inflammatory conditions like myocardial ischemia ( 106 ), acute respiratory distress syndrome ( 107 , 108 ), chronic obstructive pulmonary disease ( 109 ), post infectious bronchiolitis obliterans ( 110 ) and sepsis-induced multi organ injury ( 111 ). IL-18 has also received increase attention in the pathophysiology of neuro-vascular diseases such as in intracerebral hemorrhage ( 112 ), Japanese encephalitis ( 113 ), ocular Behcet disease ( 114 ), abdominal aortic aneurysm ( 115 ), amyotrophic lateral sclerosis ( 116 ), glioma ( 117 ) and most interestingly in cognitive impairment ( 118 ) and agitation in severe mental disease ( 119 ).…”

Section: Pathophysiological Autoimmune Conditions Associated With Il-18mentioning

confidence: 99%

Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment

et al. 2022

View full text Add to dashboard Cite

Interleukin-18 (IL-18) is a potent pro-inflammatory cytokine involved in host defense against infections and regulates the innate and acquired immune response. IL-18 is produced by both hematopoietic and non-hematopoietic cells, including monocytes, macrophages, keratinocytes and mesenchymal cell. IL-18 could potentially induce inflammatory and cytotoxic immune cell activities leading to autoimmunity. Its elevated levels have been reported in the blood of patients with some immune-related diseases, including rheumatoid arthritis, systemic lupus erythematosus, type I diabetes mellitus, atopic dermatitis, psoriasis, and inflammatory bowel disease. In the present review, we aimed to summarize the biological properties of IL-18 and its pathological role in different autoimmune diseases. We also reported some monoclonal antibodies and drugs targeting IL-18. Most of these monoclonal antibodies and drugs have only produced partial effectiveness or complete ineffectiveness in vitro, in vivo and human studies. The ineffectiveness of these drugs targeting IL-18 may be largely due to the loophole caused by the involvement of other cytokines and proteins in the signaling pathway of many inflammatory diseases besides the involvement of IL-18. Combination drug therapies, that focus on IL-18 inhibition, in addition to other cytokines, are highly recommended to be considered as an important area of research that needs to be explored.

show abstract

Section: Pathophysiological Autoimmune Conditions Associated With Il-18mentioning

confidence: 99%

Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In contrast, the subjects of this study are diabetes patients admitted for ACS occurrence. Research reports have shown that Hs-CRP levels in ACS patients are signi cantly higher than those in stable angina patients and healthy individuals [29]. Hs-CRP peaks on the second day after the occurrence of ACS and is much higher than the reference value.…”

Section: Discussionmentioning

confidence: 90%

Value of glycemic dispersion index in predicting major adverse cardiovascular events in diabetic patients with concomitant acute coronary syndrome

Shi,

Feng,

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: This investigation aims to assess the predictive value of the glycemic dispersion index (GDI), calculated by incorporating glycated hemoglobin, fasting plasma glucose, and 2-hour postprandial plasma glucose, in predicting major adverse cardiovascular events (MACE) within a 12-month timeframe for diabetic patients with concomitant acute coronary syndrome (ACS). Methods A total of 3261 diabetic patients diagnosed with ACS were selected from the Department of Cardiology, the Sixth Affiliated Hospital of Kunming Medical University, between January 2016 and July 2022. A thorough screening process was conducted, resulting in the inclusion of 512 patients based on the predefined exclusion criteria. Comprehensive clinical data and laboratory examination indicators were collected for all included patients. Subsequently, a follow-up was carried out for 12 months, with the last follow-up being concluded on July 31, 2023. During this period, the occurrence of MACE was meticulously recorded for each enrolled patient. Based on the GDI calculated for the enrolled patients, they were divided into quartile groups. A comparative analysis was performed to evaluate the clinical data and laboratory indicators among these groups. Additionally, the incidence of MACE in each quartile group was calculated. To further identify the risk factors associated with MACE in diabetic patients with concomitant ACS, COX proportional hazards regression analysis and Kaplan-Meier survival analysis were conducted. Finally, the cumulative risk of MACE over time was compared among the different study groups. Results The patients included in the study were sorted into four groups, Q1, Q2, Q3, and Q4, according to their GDI levels, from lowest to highest. The respective proportions of MACE in the Q1 to Q4 groups were 10.16%, 12.50%, 15.63%, and 16.41%. GDI, STEMI, TC, TG, LDL, and hs-CRP independently predicted the hazards for MACE in diabetic individuals with ACS. The cumulative risk of MACE over time was considerably more significant in those with a GDI > 4.21 than those with a GDI ≤ 4.21. Conclusion The elevated GDI is correlated with an augmented risk of MACE in diabetic patients with concomitant ACS, thereby serving as an early indicator for assessing the unfavorable clinical prognosis of patients.

show abstract

“…In addition, CRP is a marker of early myocardial injury that can be elevated within hours of the onset of myocardial damage. High-sensitivity CRP (hs-CRP) predicts the risk of cardiac events in asymptomatic populations and can assess the outcome of patients with acute coronary syndromes[ 36 , 37 ]. Chronic hyperglycaemia can induce vascular endothelial cell injury and an inflammatory response leading to DPN, while the inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 can stimulate CRP synthesis in vivo [ 38 ].…”

Section: Cardiovascular Inflammatory Markersmentioning

confidence: 99%

Advances in cardiovascular-related biomarkers to predict diabetic peripheral neuropathy

Cheng¹,

Guo²,

Kang³

et al. 2023

World J Diabetes

View full text Add to dashboard Cite

The incidence of type 2 diabetes mellitus is growing in epidemic proportions and has become one of the most critical public health concerns. Cardiovascular complications associated with diabetes are the leading cause of morbidity and mortality. The cardiovascular diseases that accompany diabetes include angina, myocardial infarction, stroke, peripheral artery disease, and congestive heart failure. Among the various risk factors generated secondary to hyperglycemic situations, advanced glycation end products (AGEs) are one of the important targets for future diagnosis and prevention of diabetes. In the last decade, AGEs have drawn a lot of attention due to their involvement in diabetic patho-physiology. AGEs can be derived exogenously and endogenously through various pathways. These are a nonhomogeneous, chemically diverse group of compounds formed nonenzymatically by condensation between carbonyl groups of reducing sugars and free amino groups of protein, lipids, and nucleic acid. AGEs mediate their pathological effects at the cellular and extracellular levels by multiple pathways. At the cellular level, they activate signaling cascades via the receptor for AGEs and initiate a complex series of intracellular signaling resulting in reactive oxygen species generation, inflammation, cellular proliferation, and fibrosis that may possibly exacerbate the damaging effects on cardiac functions in diabetics. AGEs also cause covalent modifications and cross-linking of serum and extracellular matrix proteins; altering their structure, stability, and functions. Early diagnosis of diabetes may prevent its progression to complications and decrease its associated comorbidities. In the present review, we recapitulate the role of AGEs as a crucial mediator of hyperglycemia-mediated detrimental effects in diabetes-associated complications. Furthermore, this review presents an overview of future perspectives for new therapeutic interventions to ameliorate cardiovascular complications in diabetes.

show abstract

[Retracted] Correlation Analysis of Acute Coronary Syndrome with Serum IL‐18, MMP‐9, hs‐CRP, and Plasma FIB

Cited by 5 publications

References 33 publications

Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment

Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment

Value of glycemic dispersion index in predicting major adverse cardiovascular events in diabetic patients with concomitant acute coronary syndrome

Advances in cardiovascular-related biomarkers to predict diabetic peripheral neuropathy

Contact Info

Product

Resources

About